All-new research in dermatology is available now – take a look at this month’s new and exclusive content on JDDonline.com:
- In a multicenter clinical study, investigators conduct an analysis of data on the Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
-
Authors evaluate Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia in a retrospective chart review of TA patients treated with ILK at an academic dermatology clinic.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
- The IL-17 pathway plays a crucial role in the immunopathogenesis and development of psoriasis in Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
-
A Survey of Dermatologists’ Preparedness for Natural and Manmade Disasters examines whether the dermatology field has advanced in its bioterrorism preparedness since a 2003 survey revealed 88% of dermatologists felt unprepared to respond to a biological attack.
View all February JDD content, including editor’s picks, supplements, CME activities, case reports, and more!
Read Now
You May Also Like
Treatment Adherence in Patients With Acne Vulgaris: A Narrative Review
Treatment Adherence in Patients With Acne Vulgaris: A Narrative Review
Unlocking the Adherence Puzzle in Acne Management Have you read this latest insightful review from the Journal of Drugs in Dermatology (JDD)? Acne vulgaris remains one of the most frequent…
JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic Scars: A Multi-Center Retrospective Cohort Study
JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic Scars: A Multi-Center Retrospective Cohort Study
Targeting Fibroproliferative Disorders: Could JAK Inhibitors Lower Keloid and Hypertrophic Scar Risk? Here is an essential new report from the JDD that could shift how we think about scar prevention.…
Author Spotlight: Jessica L. Feig MD PhD
Author Spotlight: Jessica L. Feig MD PhD
Check Out JDD’s Latest Author Spotlight Our current Author Spotlight features Jessica L. Feig MD PhD, one of the co-authors of JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic…
